COVID-19: String Of FDA Guidance Docs Lay Bare Enforcement Policies For Infusion Pumps, ECMO Devices, Thermometers, And More
In three separate immediately-in-effect guidance documents, the US agency says makers of infusion pumps and accessories, extracorporeal membrane oxygenation (ECMO) and cardiopulmonary bypass devices, and remote ophthalmic assessment and monitoring devices can make “limited modifications” to those products so they can be used during the ongoing novel coronavirus crisis, without the need for firms to seek out a new 510(k). A fourth guidance says clinical electronic thermometers that aren’t yet 510(k)-cleared by the FDA can be distributed for use.
You may also be interested in...
The Swedish company has seen a spike in orders of acute care products to treat COVID-19 patients and plans a multi-million investment to expand long-term ECMO production.
AdvaMed has had to adjust to the new COVID-19 reality like everyone else. In an exclusive interview with Medtech Insight, the head of the industry group says they are putting some key issues such as user-fee negotiations, anti-kickback legislation and breakthrough technologies reform on the back burner to prioritize dealing with the current crisis.
On this week’s podcast: The US FDA was busy with draft and final guidance documents this week, issuing three within 24 hours. The docs address disparate device industry concerns, ranging from of-the-moment issues like coronavirus test supplies, to more traditional concerns around device materials testing.